ArriVent BioPharma, Inc. Common Stock

Day range

$14.78 – $18.16

Open

$18.14

Prev close

$21.00

Volume

3.26M

Market cap

$1.04B

Shares out

49.31M

P/E

—

P/S

—

P/B

2.82

P/FCF

—

ROE

-44.6%

ROA

-41.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 19, 2026

  On October 19, 2026, ArriVent BioPharma, Inc. issued a press release announcing the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell.

• Licensing agreementAug 12, 2026

  On August 11, 2026, ArriVent BioPharma, Inc. (the "Company") entered into a Collaboration and License Agreement (the "Allist License Agreement") with Shanghai Allist Pharmaceuticals Co., Ltd. ("Allist")... the Company granted Allist an exclusive, sublicensable (through multiple tiers), royalty-bearing license under certain intellectual property owned or controlled by the Company to research, develop, manufacture, and commercialize ARR-002... for the diagnosis, prophylaxis and treatment of diseases and conditions in Greater China.

• Annual meeting resultsJun 22, 2026

  At the Annual Meeting, the stockholders: (1) elected each of James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D. to the Company's board of directors as a Class II director for a term of three years to serve until the 2029 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal ('Election of Directors'); and (2) ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ('Auditor Ratification').

• Underwriting agreementJul 2, 2025

  On July 1, 2025, ArriVent BioPharma, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the "Underwriters"), relating to the issuance and sale in an underwritten public offering (the "Offering").

• Clinical trial resultsJun 23, 2025

  On June 23, 2025, the Company announced additional follow-up proof-of-concept data from the randomized global Phase 1b FURTHER trial for first-line firmonertinib monotherapy in patients with NSCLC harboring EGFR PACC mutations. In this interim readout, patients treated with 240 mg of firmonertinib were observed to experience 16.0 months median progression free survival (mPFS) and 14.6 months median duration of response by blinded independent central review (BICR).

Days to cover

11.3

Short interest

8.45M

Avg volume

751.3K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
  positiveGlobeNewswire Inc.· Oct 25, 2026
• ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
  positiveGlobeNewswire Inc.· Oct 23, 2026
• ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
  positiveGlobeNewswire Inc.· May 7, 2026
• ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
  positiveGlobeNewswire Inc.· Mar 17, 2026
• $207B Market Shift: The Race for Fast Track Approval in Oncology
  positiveBenzinga· Feb 5, 2026